» Articles » PMID: 1323276

Influences of Cholecystokinin Octapeptide on Phosphoinositide Turnover in Neonatal-rat Brain Cells

Overview
Journal Biochem J
Specialty Biochemistry
Date 1992 Aug 1
PMID 1323276
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Cholecystokinin octapeptide (CCK-8) has been shown to be coupled to phosphoinositide turnover in pancreatic acini as well as in a kind of neuroblastoma cell and a human embryonic cell line. Little is known, however, about its link with phosphatidylinositol breakdown in the brain. The brains (minus cerebella) from 1-2-day-old neonatal rats were enzymically dissociated into single cells. The intact cells were prelabelled by incubation with myo-[3H]inositol for 3 h, and were then stimulated with agonists in the presence of 10 mM-LiCl. Carbachol at 1 mM induced an increase in InsP3 labelling in brain cells (peak at 30 min, and then a gradual decrease), and a static accumulation of InsP with time, whereas the labelling of InsP2 remained essentially unchanged. A very similar time-response curve was obtained for 10 nM-CCK-8 in stimulating phosphoinositide turnover. The dose-response curve for incubated brain cells revealed that the formation of InsP3 increased when the concentration of CCK-8 was increased from 0.1 to 10 nM. A further increase in CCK-8 concentration to 100-1000 nM resulted in a gradual decrease in InsP3 formation. InsP and InsP2 levels stayed relatively stable. The production of InsP3 stimulated by 10 nM-CCK-8 was dose-dependently suppressed by the CCK-A antagonist Devazepide in the concentration range 1-10 nM; the effect declined when the concentration was further increased to 100-1000 nM. In contrast, the CCK-B antagonist L365,260 showed a sustained suppression of InsP3 production at concentrations above 0.1 nM, i.e. in the range 1-1000 nM. The results provide evidence that CCK-8 stimulates the turnover of phosphoinositide and increases InsP3 labelling in dissociated neonatal-rat brain cells, in which both CCK-A and CCK-B receptors seem to be involved.

Citing Articles

Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Shlik J, Vasar E, Bradwejn J CNS Drugs. 2013; 8(2):134-52.

PMID: 23338219 DOI: 10.2165/00023210-199708020-00005.

References
1.
Vanderhaeghen J, Signeau J, GEPTS W . New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature. 1975; 257(5527):604-5. DOI: 10.1038/257604a0. View

2.
Rehfeld J . Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog. J Biol Chem. 1978; 253(11):4022-30. View

3.
Willems P, van Nooij I, de Pont J . Stimulatory and inhibitory effects of TMB-8 on pancreatic enzyme secretion. Biochim Biophys Acta. 1986; 888(3):255-62. DOI: 10.1016/0167-4889(86)90223-5. View

4.
Macdonald R, Werz M . Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones. J Physiol. 1986; 377:237-49. PMC: 1182830. DOI: 10.1113/jphysiol.1986.sp016184. View

5.
Barrett R, Steffey M, Wolfram C . Type-A cholecystokinin receptors in CHP212 neuroblastoma cells: evidence for association with G protein and activation of phosphoinositide hydrolysis. Mol Pharmacol. 1989; 35(4):394-400. View